Objective: To evaluate the safety and efficacy of combining artemether (AM) and praziquantel (PZQ) in different regimens for treating acute schistosomiasis japonica.

Methods: We undertook a randomized, double-blind, placebo-controlled trial within four specialized schistosomiasis hospitals in the Dongting Lake region, Hunan province, China, between May 2003 and December 2005. Study participants were randomized into one of four treatment regimes: group A received 60 mg/kg PZQ + 6 mg/kg AM; group B received 60 mg/kg PZQ + AM placebo; group C received 120 mg/kg PZQ + 6 mg/kg AM; and group D received 120 mg/kg PZQ + AM placebo. All participants were followed up over a 45-day period. The primary endpoint of the trial was human infection status (determined by positive stool examination). Secondary endpoints involved clinical observations and blood biochemistry, including monitoring haemoglobin and alanine aminotransferase levels over time.

Findings: Treatment efficacies of the four different treatment regimens were 98.0%, 96.4%, 97.7% and 95.7% for group A, B, C, and D respectively (P > 0.05). The group B had a greater treatment efficacy (96.4%) than the group D (95.7%) (P > 0.05). Group A treatment was better for clearance of fever (P < 0.05) and resulted in a shorter hospitalization time (P < 0.05).

Conclusion: This is the first report of a randomized, double-blind, placebo-controlled trial for evaluating combined chemotherapy with AM and two different dosages (60 mg/kg and 120 mg/kg) of PZQ in the treatment of acute schistosomiasis japonica in China. The combination of AM and PZQ chemotherapy did not improve treatment efficacy compared with PZQ alone. PZQ given as a dosage of 60 mg/kg (1 day, 3 x 20 mg/kg doses at 4-5 hour intervals) may be as effective as a dosage of 120 mg/kg (6 days, 20 mg/kg for each day split into 3 doses at 4-5 hour intervals).

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC2649525PMC
http://dx.doi.org/10.2471/blt.08.053041DOI Listing

Publication Analysis

Top Keywords

mg/kg pzq
20
group received
16
120 mg/kg
16
randomized double-blind
12
double-blind placebo-controlled
12
placebo-controlled trial
12
acute schistosomiasis
12
mg/kg
12
pzq
9
safety efficacy
8

Similar Publications

Praziquantel alone is insufficient for the control of schistosomiasis due to poor efficacy against juvenile worms and increasing concerns about the risk of drug resistance. We compared the efficacy and safety of praziquantel combined with four different artemisinin-based combinations to praziquantel alone in treating infection in Kenyan children. In this randomized, open-label, five-arm, head-to-head, non-inferiority trial, children (aged 9-15 years) with infection according to duplicate Kato Katz thick smears from a stool sample in the Mwea irrigation scheme of central Kenya, were enrolled.

View Article and Find Full Text PDF

Praziquantel (PZQ) is the standard treatment for schistosomiasis; however, it is poorly effective on immature and juvenile worms. The present study aimed to evaluate the therapeutic efficacy of praziquantel loaded-chitosan nanoparticles (PZQ-CSNPs) on the 25 days old juvenile Schistosoma mansoni worms compared to PZQ and chitosan nanoparticles (CSNPs). It was conducted on 60 Swiss albino mice, including 20 control and 40 experimental mice.

View Article and Find Full Text PDF

Safety and efficacy of praziquantel in pregnant women infected with Schistosoma haematobium in Lambaréné, Gabon - Clinical results from the randomized, single-blinded, controlled freeBILy-Gabon trial.

Int J Infect Dis

December 2024

Centre de Recherches Médicales de Lambaréné (CERMEL), B.P. 242 Lambaréné, Gabon; Institut für Tropenmedizin, Universität Tübingen, Wilhelmstraße 27, 72074 Tübingen, Germany; Leiden University Center for Infectious Diseases (LUCID), Leiden University Medical Center (LUMC), Department of Parasitology, Albinusdreef 2, 2333 ZA Leiden, The Netherlands; Fondation pour la Recherche Scientifique (FORS), BP:88 ISBA Cotonou, Benin; German Center for Infection Research (DZIF), Partner Site Tübingen, Braunschweig, Germany.

Objectives: Despite evidence of praziquantel's (PZQ) safety for treating schistosomiasis in pregnancy, many countries withhold treatment. Only two randomized controlled trials have investigated PZQ in pregnancy, none involving Schistosoma haematobium.

Methods: Pregnant women during the second trimester in Lambaréné (Gabon) were screened for S.

View Article and Find Full Text PDF

Bilharziasis is a widespread trematode parasite that poses a severe public health burden. Dandelion () has several pharmacological and traditional properties critical for treating several hepatic disorders. The present study was designed to assess the potential efficacy of root (TOR) dietary supplementation with or without praziquantel (PZQ) against liver and intestinal disorders in mice infected with .

View Article and Find Full Text PDF

Background: Cystic echinococcosis (CE) is a chronic disease considered a neglected one. Cystic echinococcosis is endemic in Uruguay and the region. Surgery, using various technical approaches, has the potential to safely remove the cyst(s) and lead to a complete cure in a high number of patients with simple forms of CE.

View Article and Find Full Text PDF

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!